Zilebesiran--pierwszy lek oparty na technologii siRNA w terapii nadciśnienia tętniczego.
S Surma, K Narkiewicz - Heart & Vascular Diseases …, 2023 - search.ebscohost.com
Nadciśnienie tętnicze jest najczęstszym czynnikiem ryzyka chorób układu sercowo-
naczyniowego (CVD) na świecie. W ostatnich 30 latach częstość występowania …
naczyniowego (CVD) na świecie. W ostatnich 30 latach częstość występowania …
[PDF][PDF] Hypertension Cure Research Progress: The Use of Zilebesiran in Hypertension
A Al-Mosawi - 2023 - academia.edu
Chronic hypertension is a lifelong condition, and the patients need lifelong treatment with
oral anti-hypertensive medications to say healthy and to prevent the development of serious …
oral anti-hypertensive medications to say healthy and to prevent the development of serious …
[DOC][DOC] Small interfering RNA (siRNA) therapeutics in hypertension: a viewpoint on vasopressor and vasopressor-sparing strategies for counteracting blood pressure …
P Ranasinghe, ML Addison, DJ Webb, ML Addison - research.ed.ac.uk
Hypertension is an extremely common non-communicable condition, affecting an estimated
1.3 billion adults (30-79 years) worldwide and with a prevalence that has doubled over the …
1.3 billion adults (30-79 years) worldwide and with a prevalence that has doubled over the …
Cardiovascular disease is ushering in a new era of biotechnological drugs therapy
L Yuhua, C Xiang, C Longxian - J Clin Cardiol, 2023 - lcxxgen.whuhzzs.com
In recent years, biotechnology drugs are emerging in the treatment of cardiovascular
disease, include polypeptides, monoclonal antibody (mAb), antisense oligonucleotide …
disease, include polypeptides, monoclonal antibody (mAb), antisense oligonucleotide …
Progress of bio-targeted treatment for hypertension
QIN Ping, L Yuhua, QIU Zhihua - J Clin Cardiol, 2023 - lcxxgen.whuhzzs.com
Effective prevention and treatment of hypertension reduce the risk of cardiovascular death.
However, the rate of awareness, treatment, and control for hypertension in China is still low …
However, the rate of awareness, treatment, and control for hypertension in China is still low …